Also, in the SHARP trial [21], it was reported that a low VEGF-A plasma baseline level, as a prognostic independent factor, can predict outcomes in patients with advanced HCC, both in the entire patient population and in the placebo cohort [21]. This evidence concerns the gene VEGFA and hepatocellular carcinoma.